Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

2710 Reed Road, Suite 160, Houston, United States

moneytra1n Sep. 8 at 2:00 AM

$PSTV This is what happens when you get new pumpers with no idea of the dilution awaiting to be unleashed. 33MM shares in an s-1 thats already filed. Yeesh

0 · Reply

moneytra1n Sep. 8 at 1:38 AM

$PSTV This poster will pump until the 33MM shares of dilution get unleashed then they will disappear. Their only job is to get retail to buy. Dont fall for it.

0 · Reply

Keywest20 Sep. 7 at 11:42 PM

$PSTV great news about your mother. Glad she’s coming home to be with the family and I hope tomorrow we just kick some ass looking forward to it.

0 · Reply

Beachbum1978 Sep. 7 at 10:02 PM

$PSTV A photo of the Moon in Northumberland UK, tonight.

0 · Reply

LocalYokel1967 Sep. 7 at 9:19 PM

$PSTV hope you're all having a great weekend community. Tomorrow we try to bring my Mom home to see if maybe being home will help her to get focused, I'll take all prayers and good thoughts. The conference starts tomorrow so expect some added volume and price action. I'd be very surprised if we don't get some additional filings or PR news as well so it could be a great week. I'll be adding to my position in the morning before I leave the house. Buckle up folks, it could be a fun ride.

1 · Reply

Bennyman369 Sep. 7 at 7:08 PM

$PSTV

0 · Reply

Freedom5567 Sep. 7 at 7:03 PM

$PSTV if anyone here is lucky enough to get in on the chat with Marc, One good question that I can think of would be “CNSide targets a total U.S. addressable market of roughly $6 billion. Based on your launch in Texas, the upcoming nationwide rollout, and standard-of-care adoption, what portion of that market do you realistically think PSTV could capture by the end of 2026?”

1 · Reply

ya33 Sep. 7 at 4:03 PM

$PSTV

1 · Reply

Vulnerable Sep. 7 at 12:39 AM

$PSTV Or it could look like it has for the last 5 years...since there is a R/S coming, cash poor, dilution happening, strong resistance, results are not even to phase 3, and of course shorts, aka mo, aka L2L is in control.

3 · Reply

Zackman11 Sep. 6 at 10:30 PM

$PSTV bullish for open on Monday !

1 · Reply

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 12 days ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 20 days ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 23 days ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 24 days ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 7:30 AM EDT - 24 days ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Jul 31, 2025, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 15, 2025, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 10, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 2 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 24, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

May 30, 2025, 4:15 PM EDT - 3 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 23, 2025, 4:15 PM EDT - 3 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 14, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 8, 2025, 7:00 AM EDT - 4 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Apr 23, 2025, 8:00 AM EDT - 4 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 15, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Mar 27, 2025, 7:42 PM EDT - 5 months ago

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 5 months ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 19, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 11, 2025, 11:00 AM EDT - 6 months ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 10, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 7, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 6, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Mar 5, 2025, 4:01 PM EST - 6 months ago

Plus Therapeutics Announces New Employment Inducement Grants

Mar 4, 2025, 2:06 PM EST - 6 months ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Feb 26, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Feb 24, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Feb 20, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Feb 18, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Dec 17, 2024, 7:30 AM EST - 9 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 7:30 AM EST - 9 months ago

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 3, 2024, 7:30 AM EST - 9 months ago

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Nov 25, 2024, 7:30 AM EST - 10 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Nov 22, 2024, 7:30 AM EST - 10 months ago

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Nov 21, 2024, 7:30 AM EST - 10 months ago

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Nov 16, 2024, 2:45 PM EST - 10 months ago

Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:15 PM EST - 10 months ago

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 7:30 AM EST - 10 months ago

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Nov 5, 2024, 7:30 AM EST - 10 months ago

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Oct 29, 2024, 7:30 AM EDT - 11 months ago

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting

Sep 18, 2024, 7:30 AM EDT - 1 year ago

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

moneytra1n Sep. 8 at 2:00 AM

$PSTV This is what happens when you get new pumpers with no idea of the dilution awaiting to be unleashed. 33MM shares in an s-1 thats already filed. Yeesh

0 · Reply

moneytra1n Sep. 8 at 1:38 AM

$PSTV This poster will pump until the 33MM shares of dilution get unleashed then they will disappear. Their only job is to get retail to buy. Dont fall for it.

0 · Reply

Keywest20 Sep. 7 at 11:42 PM

$PSTV great news about your mother. Glad she’s coming home to be with the family and I hope tomorrow we just kick some ass looking forward to it.

0 · Reply

Beachbum1978 Sep. 7 at 10:02 PM

$PSTV A photo of the Moon in Northumberland UK, tonight.

0 · Reply

LocalYokel1967 Sep. 7 at 9:19 PM

1 · Reply

Bennyman369 Sep. 7 at 7:08 PM

$PSTV

0 · Reply

Freedom5567 Sep. 7 at 7:03 PM

1 · Reply

ya33 Sep. 7 at 4:03 PM

$PSTV

1 · Reply

Vulnerable Sep. 7 at 12:39 AM

3 · Reply

Zackman11 Sep. 6 at 10:30 PM

$PSTV bullish for open on Monday !

1 · Reply

ADAMSFBAYINVESTOR Sep. 6 at 9:40 PM

$PSTV Good me luck for Powerball tonight longs. Once i hit the jackpot i will spend $20 Millions to buy shares here. I would love to burned these shorties and teach them a life lesson. Looking forward to next week for more uptrend. Good luck to all longs!

1 · Reply

CRZX Sep. 6 at 3:43 PM

$PSTV Monday?🤔

0 · Reply

Bennyman369 Sep. 6 at 1:45 PM

$PSTV 👀👇 LFG!!!!

1 · Reply

flywithfitz81 Sep. 6 at 8:06 AM

$PSTV

0 · Reply

TheLearners Sep. 6 at 7:47 AM

$PSTV Plus Therapeutics’ recent uptick wasn’t tied to a company announcement but to broader excitement in the oncology space. Another biotech, HUTCHMED, presented strong clinical data at a major cancer conference, fueling optimism across the sector. That momentum spilled over to Plus Therapeutics, showing how investor sentiment toward oncology innovation can benefit $PSTV as it advances its own pipeline.

0 · Reply

Imr77 Sep. 6 at 7:18 AM

$PSTV looks like a run to 0.8+ at least

0 · Reply

MCapitalJ Sep. 6 at 4:14 AM

$PSTV is it time? 👀

1 · Reply

dang1976 Sep. 6 at 2:10 AM

$PSTV, no exit strategy for me!

0 · Reply

Bennyman369 Sep. 6 at 12:22 AM

$PSTV my 🎯 for the next 6-7 months. The chart could look like this.

0 · Reply

DEFCONZERO Sep. 5 at 10:22 PM

$PSTV The Company will take care of the investors - the investors will take care of the stock and the stock will take care of the run. We just need to wait for that "moon shot" PR...and it's probably coming along with a lot more eyes on this thing + volume. Unless you're averaging down, increasing your current holdings or taking an initial stake (and that window is rapidly closing) this is at least a 2 to 3 month play and at least a 5 buck stock...maybe more...maybe a lot more. Too many positives to not give us at least a return to previous highs of 1 - 2+ dollars - we just gotta wait it out. Bears will see this by the day or the week - but the longs will get the grand slam. Play the play. GLTA

0 · Reply

Y0umadBro Sep. 5 at 9:50 PM

$PSTV not too fast now, moneytrain might have a stroke

1 · Reply

MrTicker Sep. 5 at 9:46 PM

$PSTV seeing some good after hours volume. 70k wall at 51.. keep an eye on this

1 · Reply

Market Cap	48.78M
Revenue (ttm)	5.82M
Net Income (ttm)	-12.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	0.85
Profit Margin	-223.02%
Debt to Equity Ratio	0.00

Volume	5,491,100
Avg Vol	17,997,494
Day's Range	N/A - N/A
Shares Out	99.27M
Stochastic %K	69%
Beta	0.66
Analysts	Strong Sell
Price Target	$7.88